Drug development company Valo Health and Khosla Ventures Acquisition called off their merger agreement, citing unfavorable market conditions in the biotechnology sphere. The deal had a market value of $2.8 billion.
Samir Kaul, founding partner and managing director at Khosla Ventures, said the SPAC “will continue to look for other high-impact targets across a range of industries.” Read more.
